C4 Therapeutics (CCCC) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.2 million.
- C4 Therapeutics' Net Income towards Common Stockholders fell 3040.62% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 1287.62%. This contributed to the annual value of -$105.3 million for FY2024, which is 2051.2% up from last year.
- Per C4 Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$32.2 million for Q3 2025, which was down 3040.62% from -$26.0 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Net Income towards Common Stockholders registered a high of -$15.7 million during Q4 2021, and its lowest value of -$37.2 million during Q4 2022.
- In the last 5 years, C4 Therapeutics' Net Income towards Common Stockholders had a median value of -$27.0 million in 2023 and averaged -$28.1 million.
- In the last 5 years, C4 Therapeutics' Net Income towards Common Stockholders plummeted by 13748.24% in 2022 and then surged by 5068.2% in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' Net Income towards Common Stockholders stood at -$15.7 million in 2021, then tumbled by 137.48% to -$37.2 million in 2022, then increased by 6.54% to -$34.8 million in 2023, then rose by 0.52% to -$34.6 million in 2024, then grew by 6.96% to -$32.2 million in 2025.
- Its last three reported values are -$32.2 million in Q3 2025, -$26.0 million for Q2 2025, and -$26.3 million during Q1 2025.